Valneva Conference Call Summary Company Overview - **Company**: Valneva - **Industry**: Biotechnology, specializing in vaccines - **Business Model**: Fully integrated model for developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases [2][3] Core Products - **Travel Vaccines**: - **IXIARO**: Licensed vaccine against Japanese encephalitis, primarily used by the U.S. Department of Defense [5] - **DUKORAL**: Vaccine against cholera and ETEC, acquired two years ago [6] - **Chikungunya Vaccine**: Recently licensed, targeting endemic countries rather than travel markets [7][8] Financial Performance - **Sales Growth**: - Historical year-over-year growth in proprietary products, with double-digit growth rates expected to continue [10] - Total revenues projected to include approximately $15 million above product sales [28] - **Strategic Focus**: - Aim to reduce third-party product sales to below 5% of total revenue by 2026 [10] - Cash flow generation from proprietary products to support R&D investments [10][28] Lyme Disease Vaccine Development - **Partnership**: Collaborating with Pfizer on a Lyme disease vaccine, the only advanced program globally [11] - **Market Opportunity**: - Estimated 80 million people in the U.S. and 200 million in Europe live in high-risk areas [17] - Potential annual sales projected to exceed $1 billion, depending on uptake rates [18] - **Clinical Trials**: - Data readout expected in H1 2026 from a placebo-controlled study involving over 10,000 participants [19][20] - Focus on efficacy after a 3-dose priming and booster schedule [19] Other Vaccine Programs - **Chikungunya**: - Focus on outbreak preparedness in endemic countries, with ongoing pilot vaccination campaigns in Brazil [25][26] - **Shigella**: - Two phase 2 studies underway, one in children and one in adults, with early signs of efficacy being monitored [27] Strategic Vision - **Future Growth**: - Plans to leverage expertise in vaccine development to address unmet medical needs [29] - Open to strategic in-licensing or M&A to expand into new disease areas, including enteric diseases and herpes viruses [30] - **Long-term Goals**: - Aim for sustained financial self-sustainability while continuing to innovate in vaccine development [29][30] Conclusion - Valneva is positioned as a leading specialty vaccine company with a strong pipeline and strategic partnerships, particularly in the Lyme disease vaccine space, while also focusing on expanding its product offerings and maintaining financial health through proprietary sales and R&D investments [2][3][29]

Core Insights - Valneva SE and Serum Institute of India have mutually agreed to discontinue their license agreement for Valneva's single-shot chikungunya vaccine, allowing Valneva to regain full rights and control over its supply chain and commercialization efforts in endemic high-risk countries [1][2] Group 1: Company Overview - Valneva SE is a specialty vaccine company focused on developing, manufacturing, and commercializing prophylactic vaccines for infectious diseases, addressing unmet medical needs [5] - The company has advanced multiple vaccines from early R&D to approvals and currently markets three proprietary travel vaccines [6] - Valneva's revenue from its growing commercial business supports the advancement of its vaccine pipeline, which includes a Lyme disease vaccine candidate partnered with Pfizer and a Shigella vaccine candidate [7] Group 2: Chikungunya Vaccine Context - Chikungunya virus (CHIKV) is a mosquito-borne disease causing severe joint pain, fever, and other symptoms, with significant economic and medical burdens expected to grow due to climate change [3][4] - Since 2004, chikungunya has spread to over 110 countries, with more than 3.7 million cases reported in the Americas between 2013 and 2023, highlighting the disease as a major public health problem according to the WHO [4] Group 3: Strategic Partnerships and Funding - Valneva's strategic intent to regain rights to the chikungunya vaccine aligns with its commitment to support access in low-and-middle-income countries, as outlined in a funding agreement with the Coalition for Epidemic Preparedness Innovations (CEPI) [2] - CEPI aims to accelerate vaccine development and ensure equitable access, having supported over 70 vaccine candidates against high-risk pathogens [8] Group 4: Serum Institute of India Overview - Serum Institute of India is a global leader in vaccine manufacturing, with an annual capacity of 4 billion doses and a presence in over 170 countries [10][11] - The company focuses on producing affordable vaccines and has played a significant role in reducing the prices of essential vaccines, including those for Diphtheria, Tetanus, and COVID-19 [11]

Group 1: Market Overview - Several high-volatility healthcare and cannabis stocks experienced sharp after-hours gains despite a quiet news day, driven by recent catalysts and technical momentum [1] Group 2: Tilray Brands, Inc. (TLRY) - Tilray's stock rose by 11.36% after hours, reaching $13.53, following a one-for-ten reverse stock split effective December 1, and had already increased by 44.13% during the day [2] Group 3: Valneva SE (VALN) - Valneva's shares increased by 7.22% after hours to $9.31, recovering from a 3.45% decline earlier in the day, supported by positive data from its Phase 2 chikungunya vaccine trial [3] Group 4: Chemomab Therapeutics Ltd. (CMMB) - Chemomab's stock rose by 7.66% after hours to $2.39, reacting to results from its Phase 2 SPRING trial published in the American Journal of Gastroenterology [4] Group 5: Genenta Science S.p.A. (GNTA) - Genenta's shares climbed by 12.06% after hours to $1.58, rebounding from a 14.5% drop, following updated data from its TEM-GBM study in glioblastoma patients [5] Group 6: Kazia Therapeutics Limited (KZIA) - Kazia's stock increased by 10.93% after hours to $11.57, recovering from a 20% decline, after presenting new evidence for its PI3K/mTOR inhibitor at the 2025 SABCS [6] Group 7: Traws Pharma, Inc. (TRAW) - Traws Pharma's shares edged up by 8.81% after hours to $2.54, maintaining active trading momentum despite no new developments [7]